Cantor Fitzgerald Predicts XFOR FY2025 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for X4 Pharmaceuticals in a report released on Tuesday, April 1st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($0.35) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $3.00 target price on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share.

Separately, HC Wainwright reissued a “buy” rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a research note on Thursday, March 27th.

X4 Pharmaceuticals Trading Up 2.8 %

XFOR opened at $0.23 on Thursday. X4 Pharmaceuticals has a 1-year low of $0.21 and a 1-year high of $1.60. The stock has a market capitalization of $39.59 million, a PE ratio of -2.53 and a beta of 0.58. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The firm has a 50-day moving average price of $0.42 and a two-hundred day moving average price of $0.51.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.07 million.

Institutional Trading of X4 Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Cantor Fitzgerald L. P. acquired a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $30,000. Verition Fund Management LLC acquired a new position in X4 Pharmaceuticals in the third quarter valued at about $30,000. Atria Wealth Solutions Inc. acquired a new position in X4 Pharmaceuticals in the fourth quarter valued at about $44,000. Wells Fargo & Company MN boosted its holdings in X4 Pharmaceuticals by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after buying an additional 26,763 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after buying an additional 22,485 shares during the period. Institutional investors and hedge funds own 72.03% of the company’s stock.

Insider Activity

In other news, CEO Paula Ragan sold 76,473 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the transaction, the chief executive officer now owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock valued at $91,198 over the last 90 days. 1.62% of the stock is owned by company insiders.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.